Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7494265 | 0.90 | PDE5A (0.73) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A | |
| SCHEMBL27513403 | 0.90 | PDE5A (0.56) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A | |
| SCHEMBL14264654 | 0.90 | PDE5A (0.63) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A | |
| SCHEMBL4840627 | 0.89 | PDE5A (0.73) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A | |
| SCHEMBL2950681 | 0.89 | PDE5A (0.70) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A | |
| SCHEMBL1898458 | 0.88 | PDE5A (0.67) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A | |
| SCHEMBL8484400 | 0.86 | PDE5A (0.53) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A | |
| SCHEMBL3239696 | 0.82 | PDE5A (0.52) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A | |
| SCHEMBL2956590 | 0.82 | PDE5A (1.00) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A | |
| SCHEMBL3245414 | 0.81 | F2RL3 (0.67) | PDE5ASMN1; SMN2ALDH1A1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-7754751-B2 | Preferential inhibition of release of pro-inflammatory cytokines | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2010-07-13 | — | — | US | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20050215613-A1 | Preferential inhibition of release of pro-inflammatory cytokines | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2005-09-29 | — | — | US | disclosed |
| EP-1576954-A1 | Preferential inhibition of release of pro-inflammatory cytokines | Yung Shin Pharm. Ind. Co. Ltd. (TW) | 2005-09-21 | — | — | EP | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
| US-6387942-B2 | PYRAZOLYL COMPOUND; ANTICOAGULANTS, ANTIPROLIFERATIVE AGENT | YUNG SHIN PHARMACEUTICAL IND. CO. LTD (TW) | 2002-05-14 | — | — | US | disclosed |
| CN-1331076-A | Fused pyrazolyl compounds, compositions containing the same, and uses of the compounds | YONGXIN MEDICINE INDUSTRY CO L (CN) | 2002-01-16 | — | — | CN | disclosed |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2002-01-10 | — | — | US | disclosed |
| EP-1166785-A1 | Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation | Yung Shin Pharmeutical Ind. Co., Ltd. (TW) | 2002-01-02 | — | — | EP | disclosed |
| EP-0667345-B1 | 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation | YUNG SHIN PHARM IND CO LTD (TW) | 1999-09-29 | — | — | EP | disclosed |
| US-5574168-A | ANTICOAGULANTS | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 1996-11-12 | — | — | US | disclosed |
| EP-0667345-A1 | 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation | Yung Shin Pharm. Ind. Co. Ltd. (TW) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | PDE5A 255/4885SMN1; SMN2 754/4885ALDH1A1 1123/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | PDE5A 250/4885SMN1; SMN2 702/4885ALDH1A1 1193/4885 |
| US-20050215613-A1 | Preferential inhibition of release of pro-inflammatory cytokines | IL1RN, IL1R1, NFRKB | PDE5A 2439/4885SMN1; SMN2 3023/4885ALDH1A1 3052/4885 |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | F2R, HPN, F2RL1 | PDE5A 3372/4885SMN1; SMN2 1211/4885ALDH1A1 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.